NEO-MEDROL ACETATE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NEO-MEDROL ACETATE (NEO-MEDROL ACETATE).

How it works

Methylprednisolone acetate is a corticosteroid with glucocorticoid activity. It binds to the glucocorticoid receptor, leading to modulation of gene expression, suppression of inflammatory mediators (e.g., prostaglandins, leukotrienes), and inhibition of immune cell proliferation and function.

What the body does with it

Metabolism	Hepatic metabolism primarily via CYP3A4; also undergoes extrahepatic metabolism. Metabolites are inactive or weakly active.
Excretion	Primarily renal: ~75-90% as metabolites and <5% unchanged. Biliary/fecal: ~10-25%.
Half-life	Terminal half-life approximately 24-36 hours; prolonged in hepatic impairment; sufficient for once-daily dosing.
Protein binding	Approximately 90-95%, primarily bound to corticosteroid-binding globulin (CBG) and albumin.
Volume of Distribution	Approximately 0.5-1.0 L/kg; indicates extensive tissue distribution, including synovial fluid and joint spaces.
Bioavailability	Intra-articular/local injection: nearly 100% locally; oral: not applicable (parenteral only).
Onset of Action	Intra-articular, intralesional, soft tissue: within 24-48 hours; systemic effects may be delayed due to local depot effect.
Duration of Action	Intra-articular: 1-4 weeks (depends on dose and joint size); systemic duration up to 36-48 hours after single dose.

Classification & Brands

Dosing & administration

Intra-articular, intrabursal, or periarticular injection: 4-40 mg depending on joint size. For intralesional injection: 10-40 mg per lesion. For systemic use (intramuscular): 40-120 mg every 1-5 weeks as needed.

Dosage form	CREAM
Renal impairment	No specific dose adjustment required for renal impairment; use with caution in severe renal impairment due to potential fluid retention and increased risk of adrenal suppression. GFR-based modifications not established.
Liver impairment	Child-Pugh A: No adjustment. Child-Pugh B: Use with caution; consider dose reduction by 25-50% due to reduced metabolism. Child-Pugh C: Avoid use or use lowest effective dose with close monitoring.
Pediatric use	Intra-articular: 4-20 mg depending on joint size and age. Intralesional: 10-20 mg per lesion. Systemic IM: 0.5-2 mg/kg every 1-4 weeks, titrated to response. Maximum single IM dose: 120 mg.
Geriatric use	Use lowest effective dose (e.g., 4-20 mg intra-articularly or 40-80 mg IM). Monitor for hyperglycemia, osteoporosis, and infection risk. Avoid prolonged use. Dexamethasone suppression test may be unreliable.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NEO-MEDROL ACETATE (NEO-MEDROL ACETATE).

Breastfeeding	Methylprednisolone is excreted in human breast milk, with an estimated M/P ratio of 0.5–1.0. The relative infant dose is approximately 0.9–2.5% of the maternal weight-adjusted dose. At moderate doses, risk to infant is considered low, but high-dose or prolonged use may cause adrenal suppression. Caution is advised.
Teratogenic Risk	Corticosteroids like NEO-MEDROL ACETATE (methylprednisolone acetate) are associated with an increased risk of cleft palate, intrauterine growth restriction, and adrenal suppression in neonates when used during pregnancy, particularly in the first trimester. Risk is dose and duration dependent. Use only if clearly needed, weighing benefit versus risk.

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning specifically for NEO-MEDROL ACETATE. However, corticosteroids in general carry warnings for increased risk of infection, adrenal suppression, and Cushing's syndrome.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to methylprednisolone or any component; systemic fungal infections; administration of live or live-attenuated vaccines; idiopathic thrombocytopenic purpura (intramuscular use).

Clinical Precautions

Precautions

Increased susceptibility to infections; adrenal suppression; Cushing's syndrome; osteoporosis; gastrointestinal perforation; psychiatric disturbances; fluid and electrolyte imbalances; growth suppression in children; use in patients with herpes simplex keratitis, recent GI surgery, or untreated systemic infections.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

NEO-MEDROL ACETATE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NEO-MEDROL ACETATE (NEO-MEDROL ACETATE).

How it works

What the body does with it

Metabolism	Hepatic metabolism primarily via CYP3A4; also undergoes extrahepatic metabolism. Metabolites are inactive or weakly active.
Excretion	Primarily renal: ~75-90% as metabolites and <5% unchanged. Biliary/fecal: ~10-25%.
Half-life	Terminal half-life approximately 24-36 hours; prolonged in hepatic impairment; sufficient for once-daily dosing.
Protein binding	Approximately 90-95%, primarily bound to corticosteroid-binding globulin (CBG) and albumin.
Volume of Distribution	Approximately 0.5-1.0 L/kg; indicates extensive tissue distribution, including synovial fluid and joint spaces.
Bioavailability	Intra-articular/local injection: nearly 100% locally; oral: not applicable (parenteral only).
Onset of Action	Intra-articular, intralesional, soft tissue: within 24-48 hours; systemic effects may be delayed due to local depot effect.
Duration of Action	Intra-articular: 1-4 weeks (depends on dose and joint size); systemic duration up to 36-48 hours after single dose.

Classification & Brands

Dosing & administration

Dosage form	CREAM
Renal impairment	No specific dose adjustment required for renal impairment; use with caution in severe renal impairment due to potential fluid retention and increased risk of adrenal suppression. GFR-based modifications not established.
Liver impairment	Child-Pugh A: No adjustment. Child-Pugh B: Use with caution; consider dose reduction by 25-50% due to reduced metabolism. Child-Pugh C: Avoid use or use lowest effective dose with close monitoring.
Pediatric use	Intra-articular: 4-20 mg depending on joint size and age. Intralesional: 10-20 mg per lesion. Systemic IM: 0.5-2 mg/kg every 1-4 weeks, titrated to response. Maximum single IM dose: 120 mg.
Geriatric use	Use lowest effective dose (e.g., 4-20 mg intra-articularly or 40-80 mg IM). Monitor for hyperglycemia, osteoporosis, and infection risk. Avoid prolonged use. Dexamethasone suppression test may be unreliable.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NEO-MEDROL ACETATE (NEO-MEDROL ACETATE).

Breastfeeding	Methylprednisolone is excreted in human breast milk, with an estimated M/P ratio of 0.5–1.0. The relative infant dose is approximately 0.9–2.5% of the maternal weight-adjusted dose. At moderate doses, risk to infant is considered low, but high-dose or prolonged use may cause adrenal suppression. Caution is advised.
Teratogenic Risk	Corticosteroids like NEO-MEDROL ACETATE (methylprednisolone acetate) are associated with an increased risk of cleft palate, intrauterine growth restriction, and adrenal suppression in neonates when used during pregnancy, particularly in the first trimester. Risk is dose and duration dependent. Use only if clearly needed, weighing benefit versus risk.

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning specifically for NEO-MEDROL ACETATE. However, corticosteroids in general carry warnings for increased risk of infection, adrenal suppression, and Cushing's syndrome.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to methylprednisolone or any component; systemic fungal infections; administration of live or live-attenuated vaccines; idiopathic thrombocytopenic purpura (intramuscular use).